3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Conditions
Breast Neoplasms
7248
Neoplasms
4547
Prostatic Neoplasms
3494
Colorectal Neoplasms
2941
Carcinoma, Non-Small-Cell Lung
2832
Lung Neoplasms
2548
Leukemia, Myeloid, Acute
1983
Pancreatic Neoplasms
1875
Multiple Myeloma
1812
Carcinoma, Hepatocellular
1735
Neoplasm Metastasis
1587
Stomach Neoplasms
1502
Lymphoma
1457
Head and Neck Neoplasms
1437
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1435
Brain Neoplasms
1374
Melanoma
1349
Ovarian Neoplasms
1347
Leukemia
1303
Rectal Neoplasms
1270
Recurrence
1255
Colonic Neoplasms
1204
Glioblastoma
1140
Uterine Cervical Neoplasms
1098
Lymphoma, Non-Hodgkin
1066
Leukemia, Lymphocytic, Chronic, B-Cell
989
Esophageal Neoplasms
965
Lymphoma, Follicular
938
Lymphoma, Large B-Cell, Diffuse
933
Squamous Cell Carcinoma of Head and Neck
921
Interventions
pembrolizumab
1
osimertinib
1
binimetinib
1
Pemetrexed
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Interventional
×
Non-small Cell Carcinoma
×
Clear all
NCT03991819
2025-12-05
BiniPembro
University Health Network, Toronto
Phase 1
Recruiting
40 enrolled
NCT04695925
2025-10-15
TOP
Sun Yat-sen University
Phase 3
Active not recruiting
294 enrolled